News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
Argenx Commences Second Cohort of Phase 2 ARDA Study for Empasiprutant in Multifocal Motor Neuropathy
Tuesday, June 20, 2023Argenx SE a global immunology company listed on Euronext and Nasdaq under the ticker symbol ARGX has recently announced its strategy to advance to a second dose cohort in the Phase ARDA study of empasiprubart ARGX for the treatment of multifocal mot...
Seed Group and Dante Genomics Form Strategic Partnership to Drive Scientific Advancements in the MENA Region
Tuesday, June 20, 2023Dante Genomics and Seed Group have formed a strategic partnership to bring innovative genomics and precision medicine solutions to the MENA region Dante Genomics a global leader in the field specializes in personalized healthcare and has developed cu...
Beactica Therapeutics Welcomes Dr. Jarl Ulf Jungnelius to Its Board of Directors as the Company Progresses Towards Clinical-stage Activities
Monday, June 19, 2023We are pleased to announce the addition of Dr Jarl Ulf Jungnelius to the Board of Directors of Beactica Therapeutics said Dr Per Kllblad CEO of Beactica Therapeutics Dr Jungnelius brings a wealth of experience in the clinical development of oncology...
Phase II STARBURST Study of TLX250-CDx Begins with First Patient Dosed, Investigating Indication Expansion
Monday, June 19, 2023Telix Pharmaceuticals Limited ASX TLX has announced the commencement of a Phase II study for its PETCT imaging agent TLXCDx ZrDFOgirentuximab which targets carbonic anhydrase CAIX The study named STARBURST is an openlabel Phase II basket study that a...
VIVEX Biologics, Inc. Unveils the Revolutionary CYGNUS® Dual Amniotic Allograft
Sunday, June 18, 2023VIVEX Biologics Inc a prominent regenerative medicine company focused on developing naturally sourced treatments has recently received positive news The Centers for Medicare and Medicaid Services CMS has assigned a Qcode for their product called CYGN...
FDA Approves Columvi, Roche's Bispecific Antibody for Relapsed or Refractory Diffuse Large B-cell Lymphoma, Offering Fixed-Duration Treatment
Sunday, June 18, 2023Roche a pharmaceutical company has recently obtained approval from the US Food and Drug Administration FDA for its drug called Columvi glofitamabgxbm
Infant Bacterial Therapeutics' New Patent Receives Approval in Europe
Saturday, June 17, 2023Infant Bacterial Therapeutics AB IBT has recently announced that the European Patent Office has granted approval for their patent application concerning Lactobacillus reuteri This patent specifically pertains to their drug candidate IBP which is curr...
Acrobiosystems Aneuro Collaborates With Diagnostic Biochips to Enhance Neuroscience Drug Discovery
Friday, June 16, 2023ACROBiosystems and Diagnostic Biochips operating under the Aneuro brand have recently collaborated to introduce innovative in vivo electrophysiology solutions for neuroscience research Their joint efforts aim to accelerate drug discovery and commerci...
TME Pharma Granted FDA Approval for Investigational New Drug (IND) Status of NOX-A12
Friday, June 16, 2023TME Pharma NV a biotechnology company focused on developing novel therapies for the treatment of cancer by targeting the tumor microenvironment TME has announced that its Investigational New Drug IND application for its lead asset NOXA has been appro...
Alentis Therapeutics Granted FDA Clearance for ALE.C04 Development in Treating CLDN1+ Tumors
Thursday, June 15, 2023Alentis Therapeutics a biotechnology company focused on developing treatments for Claudin positive CLDN tumors and organ fibrosis has received FDA clearance for its IND Investigational New Drug application for ALEC This clearance allows Alentis to co...
